Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

senior scientist | Image credit: Ohio State University

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

By Mary Caffrey

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

November 18th 2014

Study Identifies Disparities in Lung Cancer Treatment

The study, published in the Journal of Thoracic Oncology, identified race, insurance status, and the treatment center as variables that influenced treatment received by individuals with early-stage lung cancer.

November 18th 2014

ASCO Members Take a Stand on Access to Care for Low-Income Individuals

Surabhi Dangi-Garimella, PhD

In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.

November 17th 2014

Dr Howard K. Kaufman Explains the Importance of Diagnostics on Precision Medicine

The evolving field of precision medicine is very much reliant on diagnostics, Howard K. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, said at The American Journal of Managed Care's Patient-Centered Oncology Care meeting.

November 17th 2014

AJMC's Oncology Stakeholder Summit Participants Discuss Stringencies of Data Generation and Analysis

Surabhi Dangi-Garimella, PhD

November 17th 2014

Overuse of Imaging Adds $500 Million in Healthcare Costs, 500 More Cancer Cases a Year, Study Finds

Mary K. Caffrey

November 17th 2014

Tumor Treating Fields Can Halt Glioblastomas

An electrical device glued to the scalp can slow cancer growth and prolong survival in people with the deadliest type of brain tumor, researchers reported on Saturday in Miami, at a meeting of the Society for Neuro-Oncology.

November 17th 2014

Merck's Immuno-Oncology Molecule to Be Supported by Pfizer

The collaboration between the 2 drug giants will prove a big boost to Merck's cancer immunotherapy MSB0010718C, and will also improve it's global oncology business.

November 17th 2014

After Delays, Reimbursement Approvals Seen for Diagnostic Tests

Mary K. Caffrey

November 17th 2014

AJMC Panel Explores Immuno-oncology, and What Making Cancer a Chronic Condition Means for Payers

Mary K. Caffrey

November 17th 2014

Fertility Preservation in Young Cancer Patients

Surabhi Dangi-Garimella, PhD

November 17th 2014

Merck's Pembrolizumab: Breakthrough in NSCLC

Surabhi Dangi-Garimella, PhD

November 17th 2014

Panel Members Discuss Data Quality in Oncology Care

Surabhi Dangi-Garimella, PhD

November 17th 2014

The Challenge of Developing the Ideal Patient Satisfaction Survey

Betsy Chase Steven Dâ€™Amato, BSPharm, BCOP

November 17th 2014

The Debate on Treatment Options in Early-Stage Breast Cancer

Surabhi Dangi-Garimella, PhD

November 17th 2014

AJMC Oncology Conference Helps Managed Care Stakeholders Do More for Patients Who Have Coverage, But Still Have Limits

At its third annual conference, Patient-Centered Oncology Care 2014, The American Journal of Managed Care addressed new challenges in cancer care: more patients have coverage, but they may be "underinsured" or barred from academic centers. Amid rising drug costs and regulations that threaten community practices, the head of the largest oncology organization outlined a path toward value-based reimbursement.

November 17th 2014

Nivolumab Presents Superior Survival Results in Phase 3 Melanoma Trials

In a press release based off-of results presented at the Society for Melanoma Research 2014 International Congress in Zurich, Switzerland, BMS announced results from phase 3 of the CheckMate-066 trial.

November 16th 2014

A New Glioblastoma Vaccine on the Horizon

Following encouraging results from a second phase of a phase 1 trial, the researchers have planned a second phase, to be initiated in January 2015. The vaccine will be administered to glioblastoma patients just before they begin chemotherapy.

November 16th 2014

Long-term Results of Vismodegib in Patients With Basal Cell Carcinoma Reported

Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.

November 16th 2014

Oncolytic Virus Proves Promising in Advanced Melanoma

Despite the various treatment advances in melanoma, advanced stages of the disease remain a significant challenge for oncologists. Novel methods of attacking disease vulnerabilities continue to be developed-one such technique is the use of oncolytic viruses to destroy cancer cells. A couple of studies presented an update on preclinical and clinical progress with CAVATAK, formulated using the common cold Coxsackievirus Type A21 (CVA21), during the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13—16.

November 16th 2014

Vemurafenib Treatment Beyond Progression Is Safe and Highly Effective in Patients with Metastatic Melanoma

Patients with metastatic melanoma receiving vemurafenib following disease progression showed similar or better overall response to patients without progressive disease, according to findings from an analysis reported at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.

November 16th 2014

More Good News on Pembrolizumab for Melanoma Patients Without Other Options

Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.

November 15th 2014

More Details Presented on Melanoma Diagnostic Test

Much of the news at the Society of Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors' offices with suspicious skin marks at earlier stages.

November 15th 2014

Autophagy Regulators: An Emerging Target in Melanoma

During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.

November 14th 2014

Integrating Palliative Care Into Managed Care for the Good of Patients

Mary K. Caffrey

Yesterday, speakers opened Patient-Centered Oncology Care, sponsored by The American Journal of Managed Care, with a discussion of how to bring palliative care into the mainstream in cancer care. While progress has been made, a cultural bias against discussion end-of-life issue remains an obstacle.

November 14th 2014

FDA Approves Avastin Plus Chemotherapy for Platinum-Resistant Ovarian Cancer

Genentech announced that Avastin has been approved to treated platinum-resistant ovarian cancer, inc combination with chemotherapy, which now expands Avastin's use to 6 tumor types.

November 14th 2014

Managed Care Audience Hears ASCO's Peter Yu, MD, Describe Value-Based Efforts

Mary K. Caffrey

Peter Yu, MD, president of the American Society of Clinical Oncology, (ASCO) discussed the organization's efforts throughout 2014 to reform reimbursement and take on issues of value and quality in cancer care during Patient-Centered Oncology Care, the annual gathering sponsored by The American Journal of Managed Care.

November 13th 2014

Smokers Know Tobacco Responsible for their Bladder Cancer, Study Discovers

A Kaiser Permanante study surveyed bladder cancer patients and found that current and former smokers were aware of a connection between smoking and their disease.

November 13th 2014

NICE Comes Back With a List of 40 Expensive Drugs to Be Reassessed

The cost-value discussion in oncology continues in Europe as NICE lists 40 drugs that it plans to reassess in terms of cost versus patient benefit.

November 13th 2014

Repeat Breast Surgeries an Unnecessary Burden on Patients, Survey Finds

A national survey published in JAMA Surgery identified too many repeat surgeries in women with breast cancer.

November 12th 2014

Study Points to Disparity in HPV Vaccine Uptake

At an ongoing AACR meeting on Health Disparities in cancer, researchers from the Gillings School of Global Public Health presented data showing HPV vaccine uptake among girls is lowest in states with the highest rates of cervical cancer.

...

145 146 147 148 149 150 151 152 153

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions